$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-K Financial Statement

#000153217617000008 Filed on February 09, 2017

Income Statement

Concept	2015 Q4	2015 Q3	2015 Q2
Revenue	$1.098B	$1.137B	$998.6M
YoY Change	36.86%	56.72%	50.01%
Cost Of Revenue	$110.8M	$67.20M	$60.86M
YoY Change	86.22%	99.67%	103.22%
Gross Profit	$987.2M	$1.070B	$937.8M
YoY Change	32.88%	54.63%	47.5%
Gross Profit Margin	89.9%	94.09%	93.91%
Selling, General & Admin	$295.0M	$210.0M	$174.6M
YoY Change	68.28%	45.83%	80.49%
% of Gross Profit	29.88%	19.62%	18.62%
Research & Development	$461.2M	$425.9M	$390.3M
YoY Change	31.13%	26.11%	32.54%
% of Gross Profit	46.72%	39.8%	41.62%
Depreciation & Amortization	$22.90M	$20.70M	$15.30M
YoY Change	62.41%	46.81%	17.69%
% of Gross Profit	2.32%	1.93%	1.63%
Operating Expenses	$756.2M	$635.9M	$564.9M
YoY Change	331.36%	32.01%	44.39%
Operating Profit	$231.0M	$392.4M	$344.9M
YoY Change	7.04%	108.22%	51.19%
Interest Expense	-$3.600M	$1.715M	$2.748M
YoY Change	-43.75%	-81.42%	-73.0%
% of Operating Profit	-1.56%	0.44%	0.8%
Other Income/Expense, Net	$1.800M	$867.0K	-$16.86M
YoY Change	-40.0%	-113.06%	-12.57%
Pretax Income	$227.3M	$393.3M	$328.0M
YoY Change	19.81%	116.3%	57.08%
Income Tax	$72.30M	$182.9M	$133.4M
% Of Pretax Income	31.81%	46.5%	40.66%
Net Earnings	$155.0M	$210.4M	$194.6M
YoY Change	72.03%	152.35%	102.01%
Net Earnings / Revenue	14.12%	18.5%	19.49%
Basic Earnings Per Share	$1.49	$2.04	$1.89
Diluted Earnings Per Share	$1.34	$1.82	$1.69
COMMON SHARES
Basic Shares Outstanding		103.3M shares	102.9M shares
Diluted Shares Outstanding		115.9M shares	115.3M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.045B	$896.0M	$604.0M
YoY Change	16.11%	-14.01%	-26.07%
Cash & Equivalents	$809.1M	$654.6M	$390.6M
Short-Term Investments	$236.0M	$241.0M	$214.0M
Other Short-Term Assets	$200.0M	$182.0M	$142.0M
YoY Change	25.79%	30.94%	12.7%
Inventory	$238.6M	$190.7M	$171.3M
Prepaid Expenses
Receivables	$1.152B	$1.088B	$1.072B
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.915B	$2.676B	$2.283B
YoY Change	39.83%	21.59%	19.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.594B	$1.475B	$1.326B
YoY Change	63.62%	80.12%	87.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$632.0M	$681.0M	$590.0M
YoY Change	37.39%	50.33%	7.08%
Other Assets	$5.810M	$4.583M	$4.138M
YoY Change	91.5%	34.16%	-53.39%
Total Long-Term Assets	$2.694B	$2.507B	$2.244B
YoY Change	53.69%	62.93%	45.94%
TOTAL ASSETS
Total Short-Term Assets	$2.915B	$2.676B	$2.283B
Total Long-Term Assets	$2.694B	$2.507B	$2.244B
Total Assets	$5.609B	$5.183B	$4.527B
YoY Change	46.16%	38.6%	30.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$141.0M	$107.0M	$130.0M
YoY Change	41.0%	127.66%	176.6%
Accrued Expenses	$503.0M	$471.0M	$399.0M
YoY Change	30.99%	61.86%	69.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$811.2M	$735.0M	$601.5M
YoY Change	23.91%	79.18%	71.1%
LONG-TERM LIABILITIES
Long-Term Debt	$363.0M	$395.0M	$388.0M
YoY Change	-20.74%	-29.96%	-24.95%
Other Long-Term Liabilities	$115.5M	$77.91M	$76.08M
YoY Change	190.28%	228.08%	408.28%
Total Long-Term Liabilities	$115.5M	$77.91M	$76.08M
YoY Change	190.28%	228.08%	408.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$811.2M	$735.0M	$601.5M
Total Long-Term Liabilities	$115.5M	$77.91M	$76.08M
Total Liabilities	$1.954B	$1.886B	$1.189B
YoY Change	51.8%	58.81%	9.31%
SHAREHOLDERS EQUITY
Retained Earnings	$852.7M	$697.7M	$487.3M
YoY Change	293.6%	380.49%	644.14%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$306.1M	$288.8M	$287.1M
YoY Change	80.54%	558.57%	-754.71%
Treasury Stock Shares	3.643M shares	3.437M shares	3.417M shares
Shareholders Equity	$3.655B	$3.297B	$3.338B
YoY Change
Total Liabilities & Shareholders Equity	$5.609B	$5.183B	$4.527B
YoY Change	46.16%	38.6%	30.99%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2015 Q2
OPERATING ACTIVITIES
Net Income	$155.0M	$210.4M	$194.6M
YoY Change	72.03%	152.35%	102.01%
Depreciation, Depletion And Amortization	$22.90M	$20.70M	$15.30M
YoY Change	62.41%	46.81%	17.69%
Cash From Operating Activities	$281.8M	$892.9M	$257.8M
YoY Change	42.25%	443.13%	-23.37%
INVESTING ACTIVITIES
Capital Expenditures	-$177.7M	-$146.1M	-$239.9M
YoY Change	51.23%	83.08%	238.36%
Acquisitions
YoY Change
Other Investing Activities	$54.40M	-$137.0M	-$131.8M
YoY Change	-68.77%	216.4%	178.65%
Cash From Investing Activities	-$123.3M	-$283.2M	-$371.6M
YoY Change	-317.84%	130.24%	214.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.000M	-345.7M	-3.500M
YoY Change	-98.42%	-6748.08%	-95.63%
NET CHANGE
Cash From Operating Activities	281.8M	892.9M	257.8M
Cash From Investing Activities	-123.3M	-283.2M	-371.6M
Cash From Financing Activities	-4.000M	-345.7M	-3.500M
Net Change In Cash	154.5M	264.0M	-117.3M
YoY Change	7257.14%	466.52%	-184.94%
FREE CASH FLOW
Cash From Operating Activities	$281.8M	$892.9M	$257.8M
Capital Expenditures	-$177.7M	-$146.1M	-$239.9M
Free Cash Flow	$459.5M	$1.039B	$497.7M
YoY Change	45.6%	325.47%	22.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2016Q2	dei	Entity Public Float EntityPublicFloat	35224000000	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2015Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	50700000	USD
CY2016Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	28200000	USD
CY2015Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	88297000	USD
CY2016Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	91753000	USD
CY2015Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	195986000	USD
CY2016Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	159985000	USD
CY2014	regn	Costofmanufacturing Costofmanufacturing	75988000	USD
CY2015	regn	Costofmanufacturing Costofmanufacturing	151007000	USD
CY2016	regn	Costofmanufacturing Costofmanufacturing	105070000	USD
CY2015Q4	regn	Costs Incurred By Landlord To Construct New Laboratory And Office Facilities CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities	330432000	USD
CY2016Q4	regn	Costs Incurred By Landlord To Construct New Laboratory And Office Facilities CostsIncurredByLandlordToConstructNewLaboratoryAndOfficeFacilities	554181000	USD
CY2015Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	51914000	USD
CY2016Q4	regn	Deferred Revenue Excluding Amounts From Related Party Current DeferredRevenueExcludingAmountsFromRelatedPartyCurrent	116397000	USD
CY2015Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	82015000	USD
CY2016Q4	regn	Deferred Revenue Excluding Amounts From Related Party Non Current DeferredRevenueExcludingAmountsFromRelatedPartyNonCurrent	327298000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	101573000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	115267000	USD
CY2015Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	582664000	USD
CY2016Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	503474000	USD
CY2015Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	7725000	USD
CY2016Q4	regn	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2492000	USD
CY2015Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	364708000	USD
CY2016Q4	regn	Facility Lease Obligation Including Reimbursements FacilityLeaseObligationIncludingReimbursements	353852000	USD
CY2015Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	362919000	USD
CY2016Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	351569000	USD
CY2016Q4	regn	Facility Purchase Price FacilityPurchasePrice	720000000	USD
CY2014	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	425000	shares
CY2015	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	477000	shares
CY2016	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	474000	shares
CY2016Q4	regn	Initialtermoflease Initialtermoflease	P5Y
CY2016Q4	regn	Intended Facility Financing IntendedFacilityFinancing	720000000	USD
CY2014	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	14500000	USD
CY2015	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	9700000	USD
CY2016	regn	Interest Expense In Connection With Facility Lease Obligation InterestExpenseInConnectionWithFacilityLeaseObligation	5400000	USD
CY2014	regn	Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million Leveloftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived100million	100000000	USD
CY2014	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million	500000000	USD
CY2015Q4	regn	Limitpricepershareforwarrantholderstocloseouthedgeposition Limitpricepershareforwarrantholderstocloseouthedgeposition	535.00
CY2016	regn	Loss Contingency Damages Soughtperunitproduced. LossContingencyDamagesSoughtperunitproduced.	10000	EUR
CY2014	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	148496000	USD
CY2015	regn	Maximumamountofwarrantpayable Maximumamountofwarrantpayable	-23317000	USD
CY2016	regn	Numberofdemandrightstorequirethe Companytoconductregisteredunderwrittenpublicoffering NumberofdemandrightstorequiretheCompanytoconductregisteredunderwrittenpublicoffering	3
CY2014	regn	Other Collaboration Revenue OtherCollaborationRevenue	495555000	USD
CY2015	regn	Other Collaboration Revenue OtherCollaborationRevenue	580488000	USD
CY2016	regn	Other Collaboration Revenue OtherCollaborationRevenue	744270000	USD
CY2016Q4	regn	Paymenttowardspurchaseprice Paymenttowardspurchaseprice	57000000	USD
CY2016Q4	regn	Percentage Of Prompt Pay Discount Company Accrues PercentageOfPromptPayDiscountCompanyAccrues	1
CY2014	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2016Q3	regn	Periodoverwhichwehaveobligation Periodoverwhichwehaveobligation	P5Y
CY2014Q4	regn	Reclassificationofwarrants Reclassificationofwarrants	493229	shares
CY2015Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	162152000	USD
CY2016Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	175263000	USD
CY2015Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	644112000	USD
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	879096000	USD
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	140962000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	134984000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1152489000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1343368000	USD
CY2015Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	153152000	USD
CY2016Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	92989000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	331096000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	425504000	USD
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	8572000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12840000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3099526000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3029993000	USD
CY2014	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	439278000	USD
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	405317000	USD
CY2014	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2015	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	160538000	USD
CY2016	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	143182000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	691869000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	819657000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	47789000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-294552000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-449456000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-643365000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	326815000	USD
CY2014	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	414309000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	464022000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	574887000	USD
CY2015	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	694724000	USD
CY2016	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	577874000	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2015Q4	us-gaap	Assets Assets	5609132000	USD
CY2016Q4	us-gaap	Assets Assets	6973466000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	2915095000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	3180188000	USD
CY2015Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	868283000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	1367741000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14623000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6241000	USD
CY2015Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2769000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18987000	USD
CY2015Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	856429000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	1380487000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	92000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	58000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	2769000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	18987000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	755080000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	920357000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	2677000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	18929000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	731331000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	883950000	USD
CY2015Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	23749000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	36407000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	600695000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	815040000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	236121000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	503482000	USD
CY2015Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	836816000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1318522000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Losses AvailableForSaleSecuritiesGrossRealizedLosses	0	USD
CY2015Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	760517000	USD
CY2016Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	1278283000	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	0	USD
CY2016Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	127274000	USD
CY2016	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	448494000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	32117000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	35603000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	34763000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	33942000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	33141000	USD
CY2016Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	278928000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	809102000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535203000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	113111000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	160383000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-273899000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	391565000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	592377000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	874110000	USD
CY2015Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	579834000	USD
CY2016Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	318929000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	129030000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	241702000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	194624000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	1995638000	USD
CY2015	us-gaap	Costs And Expenses CostsAndExpenses	2851812000	USD
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	3529686000	USD
CY2014	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	437038000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	686561000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	786964000	USD
CY2014	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2879000	USD
CY2015	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4004000	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-1362000	USD
CY2014	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	468635000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	719133000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	794371000	USD
CY2014	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28718000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28568000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	8769000	USD
CY2016Q4	us-gaap	Decrease In Unrecognized Tax Benefits Is Reasonably Possible DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible	22300000	USD
CY2014	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-62932000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-119849000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-377368000	USD
CY2014	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1485000	USD
CY2015	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-6475000	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	3859000	USD
CY2014	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-45526000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-130092000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-360078000	USD
CY2015Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	21294000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	231664000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	664679000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9275000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	153487000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	830772000	USD
CY2014	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	18891000	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3768000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	13431000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	51766000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	214587000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	483239000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	837998000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	461945000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	825303000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	461945000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	825303000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	483239000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	834578000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	140000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	137000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	26580000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	46471000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	21139000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	349508000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	515984000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	47520000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	37188000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3420000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	3280000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Reserves And Accruals DeferredTaxLiabilitiesDeferredExpenseReservesAndAccruals	0	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	12455000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	9275000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5559000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2014	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	13100000	USD
CY2015	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	15400000	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	17700000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	52686000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74909000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	104745000	USD
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.36
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.74
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.89
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.04
CY2015Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	6.17
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.74
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.88
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.53
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.41
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.55
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.98
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.66
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.69
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
CY2015Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.34
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	5.52
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.59
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.69
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.27
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	7.70
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.556
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.481
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.327
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.029
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.001
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.010
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.028
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.020
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.019
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.032
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.028
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.158
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.122
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.088
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.018
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.028
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.006
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.109
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.010
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.003
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.051
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.016
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.012
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	133223000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	153086000	USD
CY2014	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	439278000	USD
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	405317000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2015Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	91400000	USD
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	44100000	USD
CY2015Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	81381000	USD
CY2016Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	152525000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	18861000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	761235000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1225097000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1329815000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423109000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	589041000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	434293000	USD
CY2014	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	59847000	USD
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	276092000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	481360000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	161182000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	303657000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	253980000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34927000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	491421000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	143827000	USD
CY2014	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	53276000	USD
CY2015	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	121623000	USD
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	360078000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8403000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	608892000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	244270000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56947000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	111825000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	149776000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	45327000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	79476000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23543000	USD
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2936000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2246000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	936000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	61000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9440000	shares
CY2015	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9446000	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	10177000	shares
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-37372000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14241000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7195000	USD
CY2014	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2015	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	USD
CY2016	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	397000	USD
CY2014	us-gaap	Interest Paid Net InterestPaidNet	20348000	USD
CY2015	us-gaap	Interest Paid Net InterestPaidNet	10582000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	5454000	USD
CY2015Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	11197000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13334000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	238578000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	399356000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	59151000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	92287000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	132068000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	202301000	USD
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	6000000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	10600000	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	14000000	USD
CY2015Q4	us-gaap	Land Land	77826000	USD
CY2016Q4	us-gaap	Land Land	103906000	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	95226000	USD
CY2016Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	101101000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	1954295000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	2524221000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5609132000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6973466000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	811162000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1241495000	USD
CY2016	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	EUR
CY2015Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	236121000	USD
CY2016Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	503481000	USD
CY2015Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	632162000	USD
CY2016Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	864260000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-218547000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-262796000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-700391000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-420777000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-907601000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1046904000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	752435000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1330780000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1473396000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	338126000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	76021000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	194643000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	210398000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	154994000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	636056000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	181385000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	196218000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	264804000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	253115000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	895522000	USD
CY2014	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	338126000	USD
CY2015	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	636056000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	895919000	USD
CY2016Q4	us-gaap	Net Rentable Area NetRentableArea	300000	sqft
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-62684000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-26819000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-926000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	823919000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	1251916000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	1330741000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	51271000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	9884000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	3993000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4283000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	5090000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	5685000	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	22336000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	14312000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	15202000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	16713000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	85644000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	103512000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5810000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20294000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	27100000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	24900000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	3300000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53439000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-43679000	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-21412000	USD
CY2015Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	36162000	USD
CY2016Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	91434000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	13563000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3461000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115535000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	100385000	USD
CY2014	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-77571000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-52562000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-45139000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25312000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-12578000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6269000	USD
CY2014	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31941000	USD
CY2015	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	74889000	USD
CY2016	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	119102000	USD
CY2014	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	294552000	USD
CY2015	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	573487000	USD
CY2016	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	643365000	USD
CY2014	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	267584000	USD
CY2015	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	160537000	USD
CY2016	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	143182000	USD
CY2014	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	564188000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	557105000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	809419000	USD
CY2014	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	333006000	USD
CY2015	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	677933000	USD
CY2016	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	511941000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	163501000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	130528000	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126045000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	206358000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	126739000	USD
CY2014	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-1095000	USD
CY2015	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	26020000	USD
CY2016	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-27689000	USD
CY2014	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	476417000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	327437000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	274456000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	215462000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	48004000	USD
CY2014	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	13125000	USD
CY2015	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	15382000	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	16561000	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2015	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	125897000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1925216000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2508925000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1594120000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2083421000	USD
CY2014	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2014	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	220639000	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	166467000	USD
CY2015	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	166500000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12900000	USD
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	12894000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1271353000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1620577000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2052295000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	852700000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1748222000	USD
CY2014	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	541299000	USD
CY2015	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	758873000	USD
CY2016	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	658665000	USD
CY2014	us-gaap	Revenues Revenues	2819557000	USD
CY2015Q1	us-gaap	Revenues Revenues	869612000	USD
CY2015Q2	us-gaap	Revenues Revenues	998617000	USD
CY2015Q3	us-gaap	Revenues Revenues	1137422000	USD
CY2015Q4	us-gaap	Revenues Revenues	1098077000	USD
CY2015	us-gaap	Revenues Revenues	4103728000	USD
CY2016Q1	us-gaap	Revenues Revenues	1200849000	USD
CY2016Q2	us-gaap	Revenues Revenues	1212629000	USD
CY2016Q3	us-gaap	Revenues Revenues	1220122000	USD
CY2016Q4	us-gaap	Revenues Revenues	1226827000	USD
CY2016	us-gaap	Revenues Revenues	4860427000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1750762000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2689478000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3338390000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	519267000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	838526000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1177697000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	321750000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	459049000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	559878000	USD
CY2015	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1625113	shares
CY2016	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	121058	shares
CY2014	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	691356000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	818360000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	115182000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	1964716000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2550251000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	3654837000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	4449245000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	235776000	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3642820	shares
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3763868	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	306069000	USD
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	316240000	USD
CY2014	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2015	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26627000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	57615000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	116572000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	117166000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3014000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	2697000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	27538000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	59909000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	45575000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	3300000	USD
CY2014	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	6464000	USD
CY2015	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-952000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-42284000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	51200000	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	102100000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	107200000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	55249000	USD
CY2016Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45851000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	111855000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	193190000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	278304000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	111675000	USD
CY2015	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	162722000	USD
CY2016	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	287702000	USD
CY2014	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12801000	shares
CY2015	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12169000	shares
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	11648000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113413000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115230000	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116367000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100612000	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103061000	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104719000	shares
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments which potentially expose the Company to concentrations of credit risk consist of cash, cash equivalents, certain financial instruments, and accounts receivable. A large portion of the Company's cash is held by a few major financial institutions. In accordance with the Company's policies, the Company mandates asset diversification and monitors exposure with its counterparties. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are significant. Accounts receivable from product sales of EYLEA and ARCALYST are due from several distributors and specialty pharmacies, who are the Company's customers. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, three individual customers accounted for </font><font style="font-family:inherit;font-size:10pt;">99%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's net trade accounts receivable balances. As of December 31, 2015, two individual customers accounted for </font><font style="font-family:inherit;font-size:10pt;">94%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's net trade accounts receivable balances.The Company has contractual payment terms with each of its customers, and the Company monitors its customers' financial performance and credit worthiness so that it can properly assess and respond to any changes in their credit profile. In addition, the Company may insure a portion of its accounts receivables within its overall risk management practices. As of December 31, 2016 and 2015, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> reserves against trade accounts receivable. In addition, during the years ended December 31, 2016, 2015, and 2014, the Company did </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">t recognize any charges for write-offs of trade accounts receivable.</font></div></div>
CY2016	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue consists of U.S. sales of EYLEA and ARCALYST. Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, the Company has no further performance obligations, and returns can be reasonably estimated. The Company's written contracts with its customers stipulate product is shipped freight on board destination (FOB destination). The Company records revenue from product sales upon delivery to its customers. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company sells EYLEA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">in the United States to several distributors and specialty pharmacies. The Company sells ARCALYST in the United States to two specialty pharmacies. Under these distribution models, the distributors and specialty pharmacies generally take physical delivery of product. For EYLEA, the distributors and specialty pharmacies generally sell the product directly to healthcare providers, whereas for ARCALYST, the specialty pharmacies sell the product directly to patients. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental and other programs, distribution-related fees, and other sales-related deductions. Calculating these provisions involves estimates and judgments. The Company reviews its estimates of rebates, chargebacks, and other applicable provisions each period and records any necessary adjustments in the current period's net product sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Government Rebates and Chargebacks: </font><font style="font-family:inherit;font-size:10pt;">The Company estimates reductions to product sales for Medicaid and Veterans' Administration ("VA") programs, and for certain other qualifying federal and state government programs. Based upon the Company's contracts with government agencies, statutorily-defined discounts applicable to government-funded programs, historical experience, and estimated payer mix, the Company estimates and records an allowance for rebates and chargebacks. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, and invoices received for claims from prior quarters that have not been paid. The Company's reserves related to discounted pricing to VA, Public Health Services ("PHS"), and other institutions (collectively "qualified healthcare providers") represent the Company's estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices the Company charges to its customers (i.e., distributors and specialty pharmacies). The Company's customers charge the Company for the difference between what they pay for the products and the ultimate selling price to the qualified healthcare providers. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distribution-Related Fees: </font><font style="font-family:inherit;font-size:10pt;">The Company has written contracts with its customers that include terms for distribution-related fees. The Company estimates and records distribution and related fees due to its customers based on gross sales. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Prompt Pay Discounts: </font><font style="font-family:inherit;font-size:10pt;">No prompt pay discounts are currently offered to the Company's customers on sales of EYLEA. In connection with sales of ARCALYST, the Company offers discounts to its customers for prompt payments. The Company estimates these discounts based on customer terms and historical experience, and expects that its customers will always take advantage of this discount. Therefore, the Company accrues </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the prompt pay discount that is based on the gross amount of each ARCALYST</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:inherit;font-size:10pt;">invoice, at the time of sale.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Returns: </font><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company offers its customers a limited right to return product purchased directly from the Company, which is principally based upon the product's expiration date. The Company will accept returns for three months prior to and up to six months after the product expiration date. Product returned is generally not resalable given the nature of the Company's products and method of administration. The Company develops estimates for product returns based upon historical experience, inventory levels in the distribution channel, shelf life of the product, and other relevant factors. The Company monitors product supply levels in the distribution channel, as well as sales by its customers of EYLEA to healthcare providers and ARCALYST to patients using product-specific data provided by its customers. If necessary, the Company's estimates of product returns may be adjusted in the future based on actual returns experience, known or expected changes in the marketplace, or other factors. </font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Estimates which could have a significant impact on the Company's financial statements include provisions related to product sales, such as rebates, chargebacks, and distribution-related fees; periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements; periods over which certain clinical trial costs are recognized; fair value of stock options; inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value; capitalization of inventory costs associated with the Company's products prior to regulatory approval; provisions for loss contingencies; deferred tax asset valuation allowances; and the assessment of uncertain tax positions. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to the Company's collaborations with Sanofi and Bayer:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Sanofi collaboration revenue is the Company's share of profits or losses from commercialization of antibodies, which is provided by Sanofi, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in Bayer collaboration revenue is the Company's share of profits or losses from commercialization of EYLEA outside the United States, which is provided by Bayer, and includes an estimate of the Company's share of profits or losses for the most recent fiscal quarter.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Included in research and development expenses is the Company's share of development expenses incurred by Bayer and Sanofi, including the Company's share of Bayer and Sanofi estimated development expenses for the most recent fiscal quarter.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These estimates for the most recent period are adjusted on a prospective basis, if necessary, in the subsequent period to reflect actual amounts.</font></div></div>

Files In Submission

Name	View Source	Status
0001532176-17-000008-index-headers.html	Edgar Link	pending
0001532176-17-000008-index.html	Edgar Link	pending
0001532176-17-000008.txt	Edgar Link	pending
0001532176-17-000008-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-123116x10k.htm	Edgar Link	pending
regn-123116_chartx06558a03.jpg	Edgar Link	pending
regn-20161231.xml	Edgar Link	completed
regn-20161231.xsd	Edgar Link	pending
regn-20161231_cal.xml	Edgar Link	unprocessable
regn-20161231_def.xml	Edgar Link	unprocessable
regn-20161231_lab.xml	Edgar Link	unprocessable
regn-20161231_pre.xml	Edgar Link	unprocessable
regn-ex_10204xgoldmansachs.htm	Edgar Link	pending
regn-ex_10223xciti3rdwarra.htm	Edgar Link	pending
regn-ex_10224xcititerminat.htm	Edgar Link	pending
regn-ex_10245xcreditsuisse.htm	Edgar Link	pending
regn-ex_10263xmorganstanle.htm	Edgar Link	pending
regn-ex_1035xlandmarkpsaex.htm	Edgar Link	pending
regn-ex_211x12312016x10k.htm	Edgar Link	pending
regn-ex_231x12312016x10k.htm	Edgar Link	pending
regn-ex_311x12312016x10k.htm	Edgar Link	pending
regn-ex_312x12312016x10k.htm	Edgar Link	pending
regn-ex_32x12312016x10k.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn

2015 Q4 Form 10-K Financial Statement

#000153217617000008 Filed on February 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN REGENERON PHARMACEUTICALS, INC. Stock $regn

2015 Q4 Form 10-K Financial Statement

#000153217617000008 Filed on February 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
REGENERON PHARMACEUTICALS, INC. Stock $regn